Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders

References

• 1. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am. J. Gastroenterol. 107(11), 1755–1756 (2012).
  MedlineGoogle Scholar
• 2. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Gastroenterol. 38(6), 475–483 (2004).
  MedlineGoogle Scholar
• 3. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44(5), 854–859 (1958).
  Medline CASGoogle Scholar
• 4. Ianiro G, Maida M, Burisch J et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United European Gastroenterol. J. 6(8), 1232–1244 (2018).
  MedlineGoogle Scholar
• 5. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4), 913–6.e7 (2012).
  Medline CASGoogle Scholar
• 6. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 36(6), 503–516 (2012).
  Medline CASGoogle Scholar
• 7. Cammarota G, Ianiro G, Kelly CR et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 68(12), 2111–2121 (2019).
  Medline CASGoogle Scholar
• 8. Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66(4), 569–580 (2017).
  MedlineGoogle Scholar
• 9. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am. J. Gastroenterol. 108(2), 177–185 (2013).
  MedlineGoogle Scholar
• 10. Angelberger S, Reinisch W, Makristathis A et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am. J. Gastroenterol. 108(10), 1620–1630 (2013).
  Medline CASGoogle Scholar
• 11. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145(5), 946–953 (2013).
  MedlineGoogle Scholar
• 12. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol. 29(1), 79–84 (2013).
  MedlineGoogle Scholar
• 13. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107(5), 761–767 (2012).
  MedlineGoogle Scholar
• 14. Ianiro G, Masucci L, Quaranta G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment. Pharmacol. Ther. 48(2), 152–159 (2018).
  Medline CASGoogle Scholar
• 15. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9(2), 88–96 (2011).
  MedlineGoogle Scholar
• 16. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am. J. Gastroenterol. 95(11), 3283–3285 (2000).
  Medline CASGoogle Scholar
• 17. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent clostridium difficile infection. J. Clin. Gastroenterol. 45(Suppl.), S159–S167 (2011).
  MedlineGoogle Scholar
• 18. Bibbò S, Lopetuso LR, Ianiro G, Rienzo Di T, Gasbarrini A, Cammarota G. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J. Immunol. Res. 2014, 462740 (2014).
  MedlineGoogle Scholar
• 19. Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile Infection following fecal microbiota transplantation. mBio 7(6), e01965–16 (2016).
  MedlineGoogle Scholar
• 20. Zuo T, Wong SH, Cheung CP et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat. Commun. 9(1), 3663 (2018).
  MedlineGoogle Scholar
• 21. Weingarden AR, Dosa PI, DeWinter E et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control clostridium difficile germination and growth. PLoS ONE 11(1), e0147210 (2016).
  MedlineGoogle Scholar
• 22. Quraishi MN, Widlak M, Bhala N et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment. Pharmacol. Ther. 46(5), 479–493 (2017).
  Medline CASGoogle Scholar
• 23. Hvas CL, Dahl Jørgensen SM, Jørgensen SP et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 156(5), 1324–1332.e3 (2019).
  MedlineGoogle Scholar
• 24. Fischer M, Sipe B, Cheng YW et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 8(3), 289–302 (2017).
  Medline CASGoogle Scholar
• 25. Ianiro G, Valerio L, Masucci L et al. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin. Microbiol. Infect. 23(5), 337.e1–337.e3 (2017).
  CASGoogle Scholar
• 26. Ianiro G, Murri R, Sciumè GD et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann. Intern. Med. 171(10), 695–702 (2019).
  MedlineGoogle Scholar
• 27. Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for clostridium difficile infection after starting a program to transplant fecal microbiota. Ann. Intern. Med. 163(6), 487–488 (2015).
  MedlineGoogle Scholar
• 28. Moayyedi P, Surette MG, Kim PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149(1), 102–109.e6 (2015).
  MedlineGoogle Scholar
• 29. ossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149(1), 110–118.e4 (2015).
  MedlineGoogle Scholar
• 30. Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389(10075), 1218–1228 (2017).
  MedlineGoogle Scholar
• 31. Costello SP, Hughes PA, Waters O et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321(2), 156–164 (2019).
  MedlineGoogle Scholar
• 32. Paramsothy S, Paramsothy R, Rubin DT et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J. Crohns Colitis. 11(10), 1180–1199 (2017).
  MedlineGoogle Scholar
• 33. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1), 85–e15 (2014).
  Medline CASGoogle Scholar
• 34. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369(8), 699–710 (2013).
  Medline CASGoogle Scholar
• 35. Sokol H, Landman C, Seksik P et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome 8(1), 12 (2020).
  MedlineGoogle Scholar
• 36. Segal JP, Oke S, Hold GL, Clark SK, Faiz OD, Hart AL. Systematic review: ileoanal pouch microbiota in health and disease. Aliment. Pharmacol. Ther. 47(4), 466–477 (2018).
  Medline CASGoogle Scholar
• 37. Segal JP, Ding NS, Worley G et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm Aliment. Pharmacol. Ther. 45(5), 581–592 (2017).
  CASGoogle Scholar
• 38. Landy J, Walker AW, Li JV et al. Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci. Rep. 5, 12955 (2015).
  Medline CASGoogle Scholar
• 39. Herfarth H, Barnes EL, Long MD et al. Combined endoscopic and oral fecal microbiota transplantation in patients with antibiotic-dependent pouchitis: low clinical efficacy due to low donor microbial engraftment. Inflamm. Intest. Dis. 4(1), 1–6 (2019).
  MedlineGoogle Scholar
• 40. Nishida A, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: a case series. Clin. Case Rep. 7(4), 782–788 (2019).
  MedlineGoogle Scholar
• 41. Stallmach A, Lange K, Buening J, Sina C, Vital M, Pieper DH. Fecal microbiota transfer in patients with chronic antibiotic-refractory pouchitis. Am. J. Gastroenterol. 111(3), 441–443 (2016).
  MedlineGoogle Scholar
• 42. El-Salhy M. Nutritional management of gastrointestinal diseases and disorders. Nutrients 11(12), 3013 (2019).
  Google Scholar
• 43. Xu D, Chen VL, Steiner CA et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am. J. Gastroenterol. 114(7), 1043–1050 (2019).
  MedlineGoogle Scholar
• 44. Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 50(3), 240–248 (2019).
  MedlineGoogle Scholar
• 45. Halkjær SI, Christensen AH, Lo BZS et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut 67(12), 2107–2115 (2018).
  Medline CASGoogle Scholar
• 46. El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 69(5), 859–867 (2020).
  Medline CASGoogle Scholar
• 47. Rosshart SP, Vassallo BG, Angeletti D et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 171(5), 1015–1028.e13 (2017).
  Medline CASGoogle Scholar
• 48. Wong SH, Zhao L, Zhang X et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153(6), 1621–1633.e6 (2017).
  MedlineGoogle Scholar
• 49. Cao H, Xu M, Dong W et al. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int. J. Cancer 140(11), 2545–2556 (2017).
  Medline CASGoogle Scholar
• 50. Ma C, Han M, Heinrich B et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360(6391), eaan5931 (2018).
  MedlineGoogle Scholar
• 51. Pushalkar S, Hundeyin M, Daley D et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8(4), 403–416 (2018).
  Medline CASGoogle Scholar
• 52. Gopalakrishnan V, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371), 97–103 (2018).
  Medline CASGoogle Scholar
• 53. Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
  Medline CASGoogle Scholar
• 54. Wang Y, Wiesnoski DH, Helmink BA et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24(12), 1804–1808 (2018).
  Medline CASGoogle Scholar
• 55. Pinato DJ, Howlett S, Ottaviani D et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 5(12), 1774–1778 (2019).
  MedlineGoogle Scholar
• 56. Tacconelli E, Mazzaferri F, de Smet AM et al. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. Clin. Microbiol. Infect. 25(7), 807–817 (2019).
  Medline CASGoogle Scholar
• 57. Mullish BH, McDonald JAK, Pechlivanis A et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut 68(10), 1791–1800 (2019).
  Medline CASGoogle Scholar
• 58. Millan B, Park H, Hotte N et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin. Infect. Dis. 62(12), 1479–1486 (2016).
  Medline CASGoogle Scholar
• 59. Bilinski J, Grzesiowski P, Sorensen N et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin. Infect. Dis. 65(3), 364–370 (2017).
  Medline CASGoogle Scholar
• 60. Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal microbiota transplantation for recurrent clostridium difficile infection reduces recurrent urinary tract infection frequency. Clin. Infect. Dis. 65(10), 1745–1747 (2017).
  Medline CASGoogle Scholar
• 61. Huttner BD, de Lastours V, Wassenberg M et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin. Microbiol. Infect. 25(7), 830–838 (2019).
  Medline CASGoogle Scholar
• 62. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102(31), 11070–11075 (2005).
  Medline CASGoogle Scholar
• 63. Le Chatelier E, Nielsen T, Qin J et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464), 541–546 (2013).
  MedlineGoogle Scholar
• 64. Ridaura VK, Faith JJ, Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341(6150), 1241214 (2013).
  MedlineGoogle Scholar
• 65. Kootte RS, Levin E, Salojärvi J et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 26(4), 611–619.e6 (2017).
  Medline CASGoogle Scholar
• 66. De Groot P, Scheithauer T, Bakker GJ et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut 69(3), 502–512 (2020).
  MedlineGoogle Scholar
• 67. Allegretti JR, Kassam Z, Mullish BH et al. Effects of fecal microbiota transplantation with oral capsules in obese patients. Clin. Gastroenterol. Hepatol. 18(4), 855–863.e2 (2020).
  Medline CASGoogle Scholar
• 68. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect. Dis. 2(1), ofv004 (2015).
  MedlineGoogle Scholar
• 69. Fischer M, Kao D, Kassam Z et al. Stool donor body mass index does not affect recipient weight after a single fecal microbiota transplantation for Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 16(8), 1351–1353 (2018).
  MedlineGoogle Scholar
• 70. Tripathi A, Debelius J, Brenner DA et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15(7), 397–411 (2018).
  Medline CASGoogle Scholar
• 71. Bajaj JS, Kassam Z, Fagan A et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66(6), 1727–1738 (2017).
  Medline CASGoogle Scholar
• 72. Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology 156(6), 1921–1923.e3 (2019).
  MedlineGoogle Scholar
• 73. Bajaj JS, Salzman NH, Acharya C et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a Phase I, randomized, placebo-controlled trial. Hepatology 70(5), 1690–1703 (2019).
  Medline CASGoogle Scholar
• 74. McMillin M, DeMorrow S. Effects of bile acids on neurological function and disease. FASEB J. 30(11), 3658–3668 (2016).
  Medline CASGoogle Scholar
• 75. Kang DW, Adams JB, Gregory AC et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5(1), 10 (2017).
  MedlineGoogle Scholar
• 76. Kang DW, Adams JB, Coleman DM et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci. Rep. 9(1), 5821 (2019).
  MedlineGoogle Scholar
• 77. FDA. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. FDA Guidance Documents (2013). http://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota
  Google Scholar
• 78. Mullish BH, Quraishi MN, Segal JP et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 67(11), 1920–1941 (2018).
  MedlineGoogle Scholar
• 79. Keller JJ, Vehreschild MJ, Hvas CL et al. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterol. J. 7(10), 1408–1410 (2019).
  MedlineGoogle Scholar
• 80. Australian Government, Department of Health Therapeutic Goods Administration. TGA regulation of faecal microbiota transplant (FMT) products in Australia (2019). http://www.tga.gov.au/tga-regulation-faecal-microbiota-transplant-fmt-products-australia
  Google Scholar
• 81. FDA. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. FDA Guidance Documents - Safety & Availability (Biologics) (2019). http://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse
  Google Scholar